Logo image
Treatment of advanced ovarian cancer with sequential combination chemotherapy
Journal article   Open access   Peer reviewed

Treatment of advanced ovarian cancer with sequential combination chemotherapy

Thomas W. Griffin, Richard A. Hunter, Andrew I. Cederbaum, Won K. Tak, Allen D. Ward, Joel H. Schwartz, Thomas F. Halpin, Gary M. Strauss, Rowland N. Meyer, Marcia K. Liepman, …
Cancer, v 60(9), pp 2150-2155
01 Nov 1987
PMID: 2830953
url
https://doi.org/10.1002/1097-0142(19871101)60:9<2150::aid-cncr2820600905>3.0.co;2-0View
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze) Open

Abstract

Fifty previously untreated patients with advanced or recurrent ovarian cancer (FIGO Stages III and IV) were treated with alternating combination chemotherapy. This consisted of high‐dose doxorubicin (70 mg/m2) and cisplatin (100 mg/m2) alternated with CHF (cyclophosphamide, hexamethylmelamine, and 5‐fluorouracil). Toxicity (myelosuppression, nephropathy, and neuropathy) was infrequent and mild. Clinical response rates were high (94% responses, 62% complete clinical response), but the majority of patients had residual intraabdominal disease at second‐look surgery (75%). Thirteen patients (26%) are alive after 4 years of observation (minimum follow‐up). Survival was adversely influenced in patients who were older than 70, had Stage IV disease, residual tumor bulk greater than 2 cm, and who failed to achieve complete clinical remission. The median duration of survival (28 months) and percentage of long‐term survivors appear similar to that in other platinum‐based chemotherapy studies. Although the role of alternating combination chemotherapy in epithelial ovarian cancer remains undefined, it is likely that an alternate approach will be necessary to markedly improve survival rates for patients with this disease.

Metrics

8 Record Views
146 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being
#5 Gender Equality

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Logo image